Active Ingredient History

  • Now
Trametinib is a reversible and specific inhibitor of mitogen-activated protein kinase kinases MEK1 and MEK2 which are involved in a RAS/RAF/MEK/ERK signaling pathway and control cell growth, survival, and differentiation. By inhibiting MEK1 and MEK2 trametinib blocks dual phosphorylation of ERK1/2 and stops cell cycling. In addition, trametinib blocks BRAF pathway in the cells with BRAF V600E mutations. Trametinib (as a single agent and in combination with dabrafenib) is approved for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations.   NCATS

  • SMILES: CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C
  • Mol. Mass: 615.4
  • ALogP: 3.94
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)


$50.5441 - $201.7095

United States

$81.7190 - $394.1280
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

daborafenib plus trametinib | gsk1120212 | gsk 1120212 | gsk-1120212 | gsk1120212b | jtp74057 | jtp 74057 | jtp-74057 | mekinist | tmt212 | trametinib | trametinib dimethyl sulfoxide | trametinibum


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue